Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Prednisolon-forbehandling øger effekten af humant lymfoblastinterferon ved kronisk hepatitis B. INTERPRED Trial Group

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Integration af specialiseret palliation og onkologi

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Formodet SARS-CoV-2-dødsfald hos en tidligere rask 50-årig mand

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Akut luftvejsobstruktion grundet uerkendt akalasi efter ukompliceret vaginal fødsel

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Dansk Kvalitetsdatabase for Nyfødte (DKN) -resumé af årsrapport 2018. Indikator 9: antibiotikabehandling

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  5. Lokalanæstesitorakoskopi ved udredning af recidiverende pleuraeffusion

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Incidence and clinical presentation of groin injuries in sub-elite male soccer

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Exercise program for prevention of groin pain in football players: a cluster-randomized trial

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Administrativ organisation og ansvar

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  4. Presence and significance of TT virus in Danish patients on maintenance hemodialysis

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  • K Krogsgaard
  • P Marcellin
  • C Trepo
  • P Berthelot
  • J M Sanchez-Tapias
  • M Bassendine
  • Anna Tuyet Nhung Tran
  • D Ouzan
  • H Ring-Larsen
  • Jacob Lindberg
  • J Enriquez
  • J P Benhamou
  • N Bindslev
Vis graf over relationer
Patients (n = 213) with chronic hepatitis B were randomised to prednisolone (two weeks of 0.6 mg/kg/day, one week of 0.45 mg/kg/day and one week of 0.25 mg/kg/day) or placebo followed by two weeks rest, and were then given human lymphoblastoid interferon 10 MU daily for five days followed by 10 MU thrice weekly for 11 weeks. There were statistically significant effects of prednisolone pre-treatment on both HBeAg disappearance and HBeAg to anti-HBe seroconversion (log rank test statistics 5.43; p = 0.02 and 4.75; p = 0.03). HBeAg disappearance and HBeAg to anti-HBe seroconversion rates were 28 vs. 44% and 23 vs. 38% (placebo vs. prednisolone). Fifteen patients (7.5%) lost HBsAg. Three out of 22 cirrhotic patients (14%), one of whom received prednisolone pre-treatment, developed hepatic decompensation with a fatal outcome. Prednisolone pre-treatment, enhances the effect of lymphoblastoid interferon in chronic hepatitis B. Interferon treatment (with and without prednisolone) should be used with caution in patients with cirrhosis and avoided in patients with evidence of hepatic decompensation.
Bidragets oversatte titelPretreatment with prednisolone enhances the effect of human lymphoblastoid interferon in chronic hepatitis B
OriginalsprogDansk
TidsskriftUgeskrift for Laeger
Vol/bind160
Udgave nummer39
Sider (fra-til)5657-61
Antal sider5
ISSN0041-5782
StatusUdgivet - 21 sep. 1998

    Forskningsområder

  • Adult, Aged, Anti-Inflammatory Agents, Drug Synergism, Europe, Female, Hepatitis B Antigens, Hepatitis B Surface Antigens, Hepatitis B, Chronic, Humans, Interferon-alpha, International Cooperation, Male, Middle Aged, Prednisolone, Premedication

ID: 39005243